ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy Meeting Abstract
| Authors: | Ottmann, O. G.; Alimena, G.; DeAngelo, D. J.; Goh, Y. T.; Heinrich, M. C.; Hochhaus, A.; Hughes, T. P.; Mahon, F. X.; Mauro, M. J.; Minami, H.; Nguyen, M. H.; Rea, D.; Steegmann, J. L.; Chatterjee, A.; Iyer, V.; Martinez, N.; Vanasse, G. J.; Dong-Wook, K. |
| Abstract Title: | ABL001, a potent, allosteric inhibitor of BCR-ABL, exhibits safety and promising single- agent activity in a phase I study of patients with CML with failure of prior TKI therapy |
| Meeting Title: | 57th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 126 |
| Issue: | 23 |
| Meeting Dates: | 2015 Dec 5-8 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2015-12-03 |
| Language: | English |
| ACCESSION: | WOS:000368019000202 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V126.23.138.138 |
| Notes: | Meeting Abstract: 138 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos |
